A First-In-Human Study of Single and Multiple Ascending Doses of Oral SUL-238 in Healthy Subjects

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
The goal of this randomized, double-blind, placebo-controlled, single-center study is to evaluate the safety, tolerability, pharmacokinetics of single and multiple oral doses of SUL-238 in healthy subjects (aged ≥40 years).
Epistemonikos ID: cfc914bf4d4c220b4e0a0972844d4d47c4bfe473
First added on: May 15, 2024